Many issues have been addressed during preparation for human ocular gene therapy clinical trials in RPE65-LCA patients [12–14], but we remain uncertain about the recovery potential of the visual cortex after prolonged and severe visual deprivation from this congenital retinal defect. The gene discussed is RPE65; the disease is Leber congenital amaurosis.